Supplementary Table 3.
Associations of pain locations in 1310 CP/CPPS patients treated at a single outpatient clinic from 1998–2014
| Perineum pain | Testicular pain | Tip of penis pain | Pubic/bladder pain | Dysuria | Ejaculatory pain | |
|---|---|---|---|---|---|---|
|
| ||||||
| n=788 | n=658 | n=441 | n=798 | n=553 | n=615 | |
| Age | 43.9 (±13.0) | 43.9 (±12.8) | 44.4 (±13.8) | 44.1 (±13.6) | 44.5 (±13.6) | 42.8 (±12.6) |
| CPSI pain | 12.3 (±3.9) | 12.8 (±3.7) | 13.1 (±3.7) | 12.4 (±3.8) | 13.0 (±3.8) | 12.8 (±3.8) |
| CPSI urination | 5.1 (±3.1) | 5.3 (±3.1) | 5.6 (±3.1) | 5.5 (±3.0) | 5.9 (±3.0) | 5.4 (±3.1) |
| CPSI QoL | 8.6 (±2.7) | 8.7 (±2.7) | 8.9 (±2.4) | 8.8 (±2.6) | 8.8 (±2.6) | 8.8 (±2.6) |
| CPSI total | 26.0 (±7.8) | 26.9 (±7.5) | 27.6 (±7.2) | 26.7 (±7.4) | 27.6 (±7.5) | 27.0 (±7.5) |
| UPOINT | ||||||
| U | 575 (73.0%) | 503 (76.4%) | 348 (78.9%) | 629 (78.8%) | 454 (82.1%) | 473 (76.9%) |
| P | 223 (28.3%) | 191 (29.0%) | 113 (25.6%) | 226 (28.3%) | 156 (28.2%) | 177 (28.2%) |
| O | 418 (53.0%) | 344 (52.3%) | 226 (51.2%) | 416 (52.1%) | 294 (53.2%) | 316 (51.4%) |
| I | 274 (34.8%) | 217 (33.0%) | 153 (34.7%) | 255 (32.0%) | 194 (35.1%) | 218 (35.4%) |
| N | 262 (33.2%) | 223 (33.9%) | 132 (29.9%) | 269 (33.7%) | 182 (32.9%) | 211 (34.3%) |
| T | 443 (56.2%) | 356 (54.1%) | 225 (51.0%) | 423 (53.0%) | 293 (53.0%) | 324 (52.7%) |
| Pain locations | ||||||
| Perineum | 788 (100%) | 479 (72.8%) | 296 (67.1%) | 524 65.7%) | 362 (65.5%) | 424 (68.9%) |
| Testicular | 479 (60.8%) | 658 (100%) | 257 (58.3%) | 483 (60.5%) | 323 (58.4%) | 359 (58.4%) |
| Tip of penis | 296 (37.6%) | 257 (58.3%) | 441 (100%) | 308 (38.6%) | 280 (50.6%) | 263 (42.8%) |
| Pubic/bladder | 524 (66.5%) | 483 (73.4%) | 308 (69.8%) | 798 (100%) | 398 (72.0%) | 418 (68.0%) |
| Dysuria | 362 (45.9%) | 323 (49.1%) | 280 (63.5%) | 398 (49.9%) | 553 (100%) | 347 (56.4%) |
| Ejaculatory | 424 (53.8%) | 359 (54.6%) | 263 (59.6%) | 418 (52.4%) | 347 (62.7%) | 615 (100%) |
| Treatment by referring physician* | ||||||
| Alpha-blockers | 502 (63.7%) | 412 (62.6%) | 303 (68.7%) | 529 (66.3%) | 386 (69.8%) | 402 (65.4%) |
| Antidepressants | 136 (17.3%) | 108 (16.4%) | 72 (16.4%) | 140 (17.5%) | 98 (17.7%) | 103 (16.7%) |
| Quercetin | 311 (39.5%) | 242 (36.8%) | 168 (38.1%) | 298 (37.3%) | 210 (38.0%) | 239 (38.9%) |
| QUrol | 77 (9.8%) | 59 (9.0%) | 51 (11.6%) | 71 (8.9%) | 53 (9.6%) | 62 (10.1%) |
| Gabapentinoids | 55 (7.0%) | 49 (7.4%) | 35 (7.9%) | 55 (6.9%) | 44 (8.0%) | 43 (7.0%) |
| Acupuncture | 7 (0.9%) | 4 (0.6%) | 2 (0.5%) | 6 (0.8%) | 4 (0.7%) | 6 (1.0%) |
| Physiotherapy | 27 (3.4%) | 22 (3.3%) | 17 (3.9%) | 28 (3.5%) | 19 (3.4%) | 14 (2.3%) |
| Antibiotics | 183 (23.2%) | 142 (21.6%) | 88 (20.0%) | 179 (22.4%) | 121 (21.9%) | 138 (22.4%) |
| Prostate massage | 35 (4.4%) | 22 (3.3%) | 17 (3.9%) | 22 (2.8%) | 20 (3.6%) | 18 (2.9%) |
*
Treatment provided by referring physician prior to or at time of evaluation of presentation to chronic prostatitis clinic.
CP/CPPS: chronic prostatitis/chronic pelvic pain syndrome; CPSI: chronic prostatitis symptom index; QoL: quality of life; UPOINT: urinary (U), psychosocial (P), organ-specific (O), infection (I), neurogenic (N), and tenderness (T).